Efmoroctocog Alfa

Summary

Efmoroctocog Alfa (CHEMBL4297945) is an approved protein; indicated across 2 conditions including hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297945
Name	Efmoroctocog Alfa
Type	Protein
Max phase	4

Also known as: Efmoroctocog alfa, Efraloctocog alfa, Elocta, Eloctate, EFMOROCTOCOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04690322	PHASE4	WITHDRAWN	POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
NCT02196207	PHASE3	WITHDRAWN	Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
NCT03364998	PHASE1	COMPLETED	BAY94-9027 PK Study Comparing to Another Long Acting Product
NCT04293523	Not specified	ACTIVE_NOT_RECRUITING	A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
NCT02976753	Not specified	COMPLETED	Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
NCT03055611	Not specified	COMPLETED	A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).